At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 164 enrolled
Drug / intervention
Ramucirumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Ramucirumab for Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma. Completed, enrolled 164 participants across 45 sites in 12 countries.
Detailed Summary
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, France, Hungary, New Zealand, Poland, Romania, Russia, Slovakia, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionNov 2016
Study CompletionJun 2019
TodayJul 2026
First PostedMay 14, 2015
Enrollment StartJul 7, 2015
Primary CompletionNov 18, 2016
Study CompletionJun 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.1 years ago
Interventions
Ramucirumabdrug
Administered IV